Literature DB >> 22855293

Recurrent blood eosinophilia in ulcerative colitis is associated with severe disease and primary sclerosing cholangitis.

Arthur Barrie1, Marwa El Mourabet, Katherine Weyant, Kofi Clarke, Mahesh Gajendran, Claudia Rivers, Seo Young Park, Douglas Hartman, Melissa Saul, Miguel Regueiro, Dhiraj Yadav, David G Binion.   

Abstract

BACKGROUND AND AIMS: Eosinophils are implicated in the pathogenesis of inflammatory bowel disease (IBD). A subset of IBD patients develops blood eosinophilia, and the clinical profile of these patients is undefined. We sought to characterize IBD patients with and without eosinophilia.
METHODS: We studied a prospective registry of 1,176 IBD patients followed in a tertiary referral center. Patients who developed eosinophilia at any time were identified by electronic medical record query. We performed a chart review case-control study comparing patients with recurrent eosinophilia versus randomly selected disease-matched patients with no history of eosinophilia. Histological analysis was performed on selected cases and controls.
RESULTS: Eosinophilia at any time was more prevalent in ulcerative colitis (UC) patients than Crohn's disease patients (22.2 versus 12.7%), as was recurrent eosinophilia (3.4 versus 0.7%). UC patients with recurrent eosinophilia were predominantly male compared with the control UC population (81.3 versus 46.9%) and had higher rates of colectomy for either medically refractory disease or dysplasia/cancer than control UC patients (56.3 versus 15.6%). Primary sclerosing cholangitis (PSC) occurred in 37.5% of UC patients with recurrent eosinophilia compared with only 3.1% in the UC controls. Histological analysis of random diagnostic samples from UC patients with recurrent eosinophilia demonstrated a normal eosinophil pattern as seen in the control UC population.
CONCLUSIONS: Eosinophilia-associated UC is a subgroup of IBD associated with severe colitis and PSC. Further studies are warranted to characterize molecular mechanisms underlying eosinophilia-associated UC and to determine optimal approaches for therapy.

Entities:  

Mesh:

Year:  2012        PMID: 22855293      PMCID: PMC3530000          DOI: 10.1007/s10620-012-2329-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  26 in total

1.  Acute phase response in laparoscopic and open colectomy in colon cancer: randomized study.

Authors:  S Delgado; A M Lacy; X Filella; A Castells; J C García-Valdecasas; J M Pique; D Momblán; J Visa
Journal:  Dis Colon Rectum       Date:  2001-05       Impact factor: 4.585

2.  Prevalence of atopy is unrelated to presence of inflammatory bowel disease.

Authors:  R Troncone; T G Merrett; A Ferguson
Journal:  Clin Allergy       Date:  1988-03

3.  Primary sclerosing cholangitis associated with increased peripheral eosinophils and serum IgE.

Authors:  I Shimomura; Y Takase; S Matsumoto; J Kuyama; T Nakajima; H Maeda; T Sugase; A Hata; M Hanada; M Okuno
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

4.  Circulating and tissue eosinophils in ulcerative colitis.

Authors:  R Wright; S C Truelove
Journal:  Am J Dig Dis       Date:  1966-11

Review 5.  Role of eosinophils in inflammatory bowel and gastrointestinal diseases.

Authors:  Samantha A Woodruff; Joanne C Masterson; Sophie Fillon; Zachary D Robinson; Glenn T Furuta
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-06       Impact factor: 2.839

6.  Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon.

Authors:  K Kett; T O Rognum; P Brandtzaeg
Journal:  Gastroenterology       Date:  1987-11       Impact factor: 22.682

7.  Blood eosinophilia and ulcerative colitis--influence of ethnic origin.

Authors:  G F Benfield; P Asquith
Journal:  Postgrad Med J       Date:  1986-12       Impact factor: 2.401

8.  Elevated serum eotaxin levels in patients with inflammatory bowel disease.

Authors:  Amparo Mir; Miguel Minguez; Jose Tatay; Isabel Pascual; Antonio Peña; Vicente Sanchiz; Pedro Almela; Francisco Mora; Adolfo Benages
Journal:  Am J Gastroenterol       Date:  2002-06       Impact factor: 10.864

9.  Peripheral eosinophilia and eosinophilic gastroenteritis after pediatric liver transplantation.

Authors:  René Romero; Carlos R Abramowsky; Todd Pillen; Gregory A Smallwood; Thomas G Heffron
Journal:  Pediatr Transplant       Date:  2003-12

10.  Blood and graft eosinophilia as predictors of rejection in human liver transplantation.

Authors:  P F Foster; H N Sankary; M Hart; M Ashmann; J W Williams
Journal:  Transplantation       Date:  1989-01       Impact factor: 4.939

View more
  8 in total

1.  Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes.

Authors:  Douglas Zabrowski; Danielle Abraham; Geoffrey Rosenthal; Howard Kader
Journal:  JGH Open       Date:  2020-02-07

2.  Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype.

Authors:  Benjamin Click; Alyce M Anderson; Ioannis E Koutroubakis; Claudia Ramos Rivers; Dmitriy Babichenko; Jorge D Machicado; Douglas J Hartman; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Arthur Barrie; Sally E Wenzel; Miguel Regueiro; David G Binion
Journal:  Am J Gastroenterol       Date:  2017-11-07       Impact factor: 10.864

3.  Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis.

Authors:  Christian Rupp; Konrad Alexander Bode; Fadi Chahoud; Andreas Wannhoff; Kilian Friedrich; Karl-Heinz Weiss; Peter Sauer; Wolfgang Stremmel; Daniel Nils Gotthardt
Journal:  BMC Infect Dis       Date:  2014-10-23       Impact factor: 3.090

4.  Outcomes of inflammatory bowel disease in patients with eosinophil-predominant colonic inflammation.

Authors:  Tarik Alhmoud; Anas Gremida; Diego Colom Steele; Imaneh Fallahi; Wael Tuqan; Nina Nandy; Mahmoud Ismail; Barakat Aburajab Altamimi; Meng-Jun Xiong; Audra Kerwin; David Martin
Journal:  BMJ Open Gastroenterol       Date:  2020-02-16

Review 5.  Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?

Authors:  Inge Jacobs; Matthias Ceulemans; Lucas Wauters; Christine Breynaert; Séverine Vermeire; Bram Verstockt; Tim Vanuytsel
Journal:  Front Immunol       Date:  2021-10-19       Impact factor: 7.561

6.  Potent CCR3 Receptor Antagonist, SB328437, Suppresses Colonic Eosinophil Chemotaxis and Inflammation in the Winnie Murine Model of Spontaneous Chronic Colitis.

Authors:  Rhiannon T Filippone; Narges Dargahi; Rajaraman Eri; Jose A Uranga; Joel C Bornstein; Vasso Apostolopoulos; Kulmira Nurgali
Journal:  Int J Mol Sci       Date:  2022-07-14       Impact factor: 6.208

7.  High-throughput multi-analyte Luminex profiling implicates eotaxin-1 in ulcerative colitis.

Authors:  Lori A Coburn; Sara N Horst; Rupesh Chaturvedi; Caroline T Brown; Margaret M Allaman; Brooks P Scull; Kshipra Singh; M Blanca Piazuelo; Maithili V Chitnavis; Mallary E Hodges; Michael J Rosen; Christopher S Williams; James C Slaughter; Dawn B Beaulieu; David A Schwartz; Keith T Wilson
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

8.  Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD.

Authors:  Katarzyna Neubauer; Malgorzata Matusiewicz; Iwona Bednarz-Misa; Sabina Gorska; Andrzej Gamian; Malgorzata Krzystek-Korpacka
Journal:  Gastroenterol Res Pract       Date:  2018-07-29       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.